These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 5755194)

  • 1. [On the pharmacokinetics of rapid PAS infusions].
    Bercea O; Marcian S
    Z Tuberk Erkr Thoraxorg; 1968; 128(1):256-7. PubMed ID: 5755194
    [No Abstract]   [Full Text] [Related]  

  • 2. [Administration by slow phleboclysis of isoniazid and para-aminosalicylic acid in the treatment of tuberculosis. Therapeutic effects and blood levels of the drug].
    Mariani B; Bisetti A; Monzali G
    G Ital Mal Torace; 1967; 21(2):81-92. PubMed ID: 5602966
    [No Abstract]   [Full Text] [Related]  

  • 3. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravenous injection of isoniazid and PAS twice weekly to outpatients with tuberculosis in rural areas].
    Ursov IG; Volokitin FN; Borovinskaia TA
    Probl Tuberk; 1983 Nov; (11):42-5. PubMed ID: 6675002
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic.
    Pentikainen P; Wan SH; Azarnoff DL
    Am Rev Respir Dis; 1973 Dec; 108(6):1340-70. PubMed ID: 4751720
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of the lymphatics in the intestinal absorption and distribution of drugs.
    De Marco TJ; Levine RR
    J Pharmacol Exp Ther; 1969 Sep; 169(1):142-51. PubMed ID: 4979680
    [No Abstract]   [Full Text] [Related]  

  • 7. [PAS glucoside as an infusion solution in the treatment of cavernous pulmonary tuberculosis and tuberculous meningitis].
    EHLERT H
    Beitr Klin Tuberk Spezif Tuberkuloseforsch; 1954; 112(1):85-90. PubMed ID: 13208540
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reactive lymphocytic meningitis due to intravenous perfusion of PAS].
    Fochi Rignani E; Fazio S
    Friuli Med; 1965; 20(3):442-8. PubMed ID: 5846970
    [No Abstract]   [Full Text] [Related]  

  • 9. Importance of the type of dosage form and saturable acetylation in determining the bioactivity of p-aminosalicylic acid.
    Wagner JG; Holmes PD; Wilkinson PK; Blair DC; Stoll RG
    Am Rev Respir Dis; 1973 Sep; 108(3):536-46. PubMed ID: 4745249
    [No Abstract]   [Full Text] [Related]  

  • 10. [Metabolism of PASA during administration of the preparation once and thrice daily].
    Savula MM
    Probl Tuberk; 1967; 45(4):70-4. PubMed ID: 5606807
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.
    Wan SH; Pentikainen PJ; Azarnoff DL
    J Pharm Sci; 1974 May; 63(5):708-11. PubMed ID: 4829991
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt.
    Pentikäinen PJ; Wan SH; Azarnoff DL
    J Pharm Sci; 1974 Sep; 63(9):1431-4. PubMed ID: 4610119
    [No Abstract]   [Full Text] [Related]  

  • 13. [The level of p-aminosalicyclic acid in the blood in oral treatment with a calcium-aluminum-p-aminosalicylate].
    Mulder RJ; Huizinga T
    Ned Tijdschr Geneeskd; 1968 Sep; 112(37):1630-4. PubMed ID: 4878452
    [No Abstract]   [Full Text] [Related]  

  • 14. [Organization of laboratory control over the intake of PAS].
    Moskalev LK; Naĭda NP
    Probl Tuberk; 1970; 48(10):82-4. PubMed ID: 5496757
    [No Abstract]   [Full Text] [Related]  

  • 15. [Concentration and tolerance of INH and PAS in single daily doses. (Preliminary report)].
    Vil'derman AM; Finn ER; Busygina RN; Draganiuk KA; Ezerskiĭ VF; Evgrafova ZA
    Probl Tuberk; 1965; 43(11):30-4. PubMed ID: 5875728
    [No Abstract]   [Full Text] [Related]  

  • 16. [The secretory function of the stomach in patients with pulmonary tuberculosis during antibacterial therapy with the use of large doses of PAS].
    Petrenko VM
    Probl Tuberk; 1966; 44(4):44-9. PubMed ID: 5997395
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of p-aminosalicylic acid (PAS) in vitro on the degradation of cortisone in the rat liver].
    Mayer G
    Arzneimittelforschung; 1968 Mar; 18(3):368-9. PubMed ID: 5696017
    [No Abstract]   [Full Text] [Related]  

  • 18. [PAS electrophoresis in hemorrhoids].
    Danilova MI
    Vopr Kurortol Fizioter Lech Fiz Kult; 1973; 38(6):559-60. PubMed ID: 4783268
    [No Abstract]   [Full Text] [Related]  

  • 19. [Laboratory control over the regularity of patients' taking PAS in the hospital].
    Utkin VV; Voinova GI; Mel'nik EG; Egorkina ND; Dan'shina MIa
    Lab Delo; 1972; 11():699-701. PubMed ID: 4124384
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oral therapy instead of enemas].
    MMW Fortschr Med; 2003 Feb; 145(8):56. PubMed ID: 12661449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.